Tevosol said it named Organ Recovery Systems veteran Ron Mills to be its new CEO. “Ron knows our technology and our market,” co-founder & CSO Dr. Darren Freed said in prepared remarks. “He brings a wealth of relevant experience to our team and adds a spark of creativity to drive the next exciting stage of […]
MediWound
MediWound lands $21m extension from BARDA to support NexoBrid
MediWound (NSDQ:MDWD) said today that the U.S. Biomedical Advanced Research and Development Authority (BARDA) upsized a contract with the company to provide a supplemental $21 million in funding. The newly acquired funding will be used to help launch the NexoBrid expanded access treatment protocol with the company’s NexoBrid product. The NexoBrid is a topically-administered product intended […]
Vericel inks licensing deal for MediWound’s NexoBrid, posts Q1 earnings
Vericel (NSDQ:VCEL) said yesterday it inked an exclusive U.S. licensing and supply agreement with MediWound (NSDQ:MDWD) for its NexoBrid biological product, and reported first quarter earnings that missed expectations on Wall Street. The NexoBrid is a topically-administered product intended to enzymatically remove nonviable burn tissue in patients with deep partial and full-thickness thermal burns. The product has […]
MediWound raises $25m
MediWound (NSDQ:MDWD) today announced a $25.2 million offering to support research and development of its EscharEx topical biological drug for debridement of chronic and other hard-to-heal wounds. In the offering, the Israel-based company floated approximately 5 million shares, including 637,664 shares through an underwriter’s option. Read the whole story on our sister site, Drug Delivery Business
MediWound touts Phase II study
MediWound (NSDQ:MDWD) touted data from a phase II trial of its EscharEx topical biological drug for debridement of chronic and other hard-to-heal wounds. The data includes a follow-up period of 6 months from the last treatment to 3 months from wound closure. The randomized phase II trial enrolled 73 patients with a variety of chronic […]
